Want to see HK:6996 full AI Analyst Report?
6996 Stock Chart & Stats
HK$5.27
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.27
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$2.76 - HK$8.16
Previous CloseN/A
Volume1.25M
Average Volume (3M)1.88M
Market Cap
HK$2.71B
Enterprise ValueHK$1.30B
Total Cash (Recent Filing)HK$734.29M
Total Debt (Recent Filing)HK$257.51M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 21, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding679,446,660
10 Day Avg. Volume1,689,397
30 Day Avg. Volume1,876,149
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.32
Price to Sales (P/S)20.24
P/FCF Ratio-11.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.20Price Target Upside74.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.49
Revenue Forecast (FY)HK$708.35M
Bulls Say, Bears Say
Bulls Say
Improving Revenue Growth And Commercialization TractionSustained revenue acceleration into 2025 indicates improving commercial execution and adoption of approved products in Antengene's target Asian markets. Over a 2–6 month horizon, stronger top-line momentum supports scaling of commercialization infrastructure and increases the likelihood of continued partnership milestones and royalty inflows.
High Gross Margins Supporting Unit EconomicsA gross margin near 65% demonstrates durable product-level profitability and favorable pricing or cost structure on sales. Even with some margin compression, robust gross margins provide room to invest in R&D and commercial expansion without immediately undermining product economics, underpinning medium-term sustainability of operations.
Low Leverage And Balance-sheet FlexibilityRelatively modest leverage gives Antengene flexibility to fund near-term clinical and commercialization needs through existing capital or modest additional financing. Lower debt reduces refinancing pressure and supports strategic options—partnering, milestone-driven deals, or selective capex—over the next several months.
Bears Say
Deep Operating And Net LossesPersistent large operating and net losses signal structural profitability challenges; even with narrowing losses, ongoing negative margins mean the company must rely on external capital or partnerships to fund growth. This constrains strategic flexibility and elevates execution risk over the coming 2–6 months.
Sustained Negative Free Cash Flow And Cash BurnMaterial negative free cash flow, despite improvement, means Antengene cannot self-fund operations and product launches. Continued cash burn requires financing or milestone-driven inflows, increasing dilution or covenant risk and limiting the firm's ability to invest opportunistically in R&D or commercial expansion in the medium term.
Erosion Of Equity And Negative Returns On CapitalDeclining equity and highly negative ROE reflect capital erosion from cumulative losses, reducing financial resilience. Over several months this weakens the company's capacity to absorb setbacks, raises the bar for corrective profitability, and may pressure governance or strategic choices if capital replenishment is needed.
Antengene Corporation Limited News
6996 FAQ
What was Antengene Corporation Limited’s price range in the past 12 months?
Antengene Corporation Limited lowest stock price was HK$2.76 and its highest was HK$8.16 in the past 12 months.
What is Antengene Corporation Limited’s market cap?
Antengene Corporation Limited’s market cap is HK$2.71B.
When is Antengene Corporation Limited’s upcoming earnings report date?
Antengene Corporation Limited’s upcoming earnings report date is Aug 21, 2026 which is in 38 days.
How were Antengene Corporation Limited’s earnings last quarter?
Antengene Corporation Limited released its earnings results on Mar 20, 2026. The company reported -HK$0.301 earnings per share for the quarter, the consensus estimate of -HK$0.301 by HK$0.
Is Antengene Corporation Limited overvalued?
According to Wall Street analysts Antengene Corporation Limited’s price is currently Undervalued.
Does Antengene Corporation Limited pay dividends?
Antengene Corporation Limited does not currently pay dividends.
What is Antengene Corporation Limited’s EPS estimate?
Antengene Corporation Limited’s EPS estimate is 0.43.
How many shares outstanding does Antengene Corporation Limited have?
Antengene Corporation Limited has 679,446,660 shares outstanding.
What happened to Antengene Corporation Limited’s price movement after its last earnings report?
Antengene Corporation Limited reported an EPS of -HK$0.301 in its last earnings report, expectations of -HK$0.301. Following the earnings report the stock price went up 0.247%.
Which hedge fund is a major shareholder of Antengene Corporation Limited?
Currently, no hedge funds are holding shares in HK:6996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Antengene Corporation Limited
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
6996 Stock 12 Month Forecast
Average Price Target
HK$9.20
▲(74.57% Upside)
Technical Analysis
Innovent Biologics
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---